Migraine. Migraine, unspecified
Conditions
Interventions
Intervention 1: Intervention group: L-carnitine 500 mg tablets of Kharazmi Company are crushed and placed inside the capsule and taken once a day orally for one month to be added to the routine migrai
Sponsors
Gonabad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Signed informed consent Migraine with or without aura according to the International Classification of Headache Disorders Having 2 or more migraine attacks per month during the past 3 months Migraine onset before age 50 BMI (kg/m2) between 18 and 35
Exclusion criteria
Exclusion criteria: Absence of kidney disease or reduced kidney function and liver cirrhosis No previous use of L-carnitine No use of = 3 prophylactic medications against migraine during the past 5 years No alcohol or illegal drug addiction Not having asthma or vascular disease, arterial lameness Pregnancy, breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of days with moderate to severe headache lasting more than 4 hours or treated with usual treatments. Timepoint: Before the intervention and 4 and 8 weeks after the intervention. Method of measurement: check list. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of days with migraine. Timepoint: Before the intervention and 4 and 8 weeks after the intervention. Method of measurement: check list.;Severity of headache on days with headache. Timepoint: Before the intervention and 4 and 8 weeks after the intervention. Method of measurement: MIGSEV scale.;Doses of analgesics and triptans. Timepoint: Before the intervention and 4 and 8 weeks after the intervention. Method of measurement: check list. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNegar Shafaei Bajestani
Gonabad University of Medical Sciences
Outcome results
None listed